Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Lehigh Valley Topper Cancer Institute and the University of Michigan Health Rogel Cancer Center have joined as clinical trial sites in the Strata Sentinel^TM trial, a prospective, observational study of the StrataMRD^TM minimal residual disease test that has the potential to shift the paradigm of cancer care, bringing the use of biomarker-matched precision therapies to earlier stages of the disease.

“The Strata Sentinel trial is a key piece of our strategy of developing integrated solutions to enable smarter and earlier cancer treatment,” said Dan Rhodes, PhD, co-founder and Chief Executive Officer, Strata Oncology. “We are grateful to add Lehigh Valley Topper Cancer Institute and the University of Michigan Health Rogel Cancer Center to our growing list of partners that we are working with to not only collect clinical validation and utility data, but also to learn together to create the sustainable, scalable systems necessary to deliver the best possible treatment to every patient with cancer.”

“At Lehigh Valley Topper Cancer Institute, we are continuously working to improve cancer care, including partnering with innovators to bring the latest technology to the patients we serve,” said Suresh Nair, MD, Physician in Chief of the Lehigh Valley Topper Cancer Institute. “With the Strata Sentinel trial, we aim to demonstrate the utility of detecting recurrence as soon as possible using the ctDNA-based StrataMRD test. We will also evaluate the clinical benefit of treating patients with micrometastatic disease, including with biomarker-matched therapies chosen based on the extended treatment selection data provided by Strata Oncology platform.” 

“By helping identify cancer recurrences as early as possible, StrataMRD has tremendous potential to change how we care for patients after initial cancer treatment,” said Todd Morgan, MD, the Jack Lapides, MD, Research Professor at the University of Michigan Medical School and the Chief of Urologic Oncology at University of Michigan Health. “We are pleased to partner with Strata Oncology to not only study the impact of StrataMRD on our patient population, but to work together to establish the workflows and data management systems necessary to implement precision oncology across a health system at scale.”

Patients interested in learning more about the Strata Sentinel trial can visit ClinicalTrials.gov and search for the trial identifier: NCT05082701.